First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    ENDRA Life Sciences Inc. (NDRA): the developments shaping its investment case

    Follow the evidence affecting ENDRA Life Sciences Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research ENDRA Life Sciences Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-08-21 · 2 reports
    ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.
    Channel: Direct impact from acquiring a new business (Renergen) and a complete strategic pivot. This will fundamentally change NDRA's business model, revenue streams, and risk profile.
    mixed· 3-12m
    2026-08-17
    ENDRA Life Sciences Inc. to Acquire Noble Africa LLC
    Channel: Direct corporate action: acquisition, change in business focus, potential delisting/relisting, and significant dilution for existing shareholders. The company is pivoting from medical devices to natural gas exploration.
    mixed· 1-3m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-07-22multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.
    2026-07-22share_countBullishPrimary equity issuance increases diluted share count.
    2026-06-25multipleBullishTarget re-rates to bid premium until close.
    2026-06-25share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-06-25net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-06-25revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    3 events mapped to NDRA since 2026-08-17. Evidence through 2026-08-21.

    DateEventChannelDirectionHorizonImpact
    2026-08-21ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.Direct impact from acquiring a new business (Renergen) and a complete strategic pivot. This will fundamentally change NDRA's business model, revenue streams, and risk profile.mixed3-12m0.80
    2026-08-21ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc.Direct impact from acquisition premium and increased certainty of value realization for shareholders.Bullishintraday0.80
    2026-08-17ENDRA Life Sciences Inc. to Acquire Noble Africa LLCDirect corporate action: acquisition, change in business focus, potential delisting/relisting, and significant dilution for existing shareholders. The company is pivoting from medical devices to natural gas exploration.mixed1-3m0.80

    Continue this research

    Build your ENDRA Life Sciences Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the NDRA entity page →

    Research ENDRA Life Sciences Inc. · $399/mo